Last reviewed · How we verify

Trastuzumab/Hyaluronidase-oysk — Competitive Intelligence Brief

Trastuzumab/Hyaluronidase-oysk (Trastuzumab/Hyaluronidase-oysk) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Oncology.

phase 3 Monoclonal antibody HER2/neu receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Trastuzumab/Hyaluronidase-oysk (Trastuzumab/Hyaluronidase-oysk) — National Cancer Institute (NCI). Trastuzumab targets the HER2/neu receptor, while hyaluronidase is an enzyme that helps the drug spread more evenly throughout the body.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Trastuzumab/Hyaluronidase-oysk TARGET Trastuzumab/Hyaluronidase-oysk National Cancer Institute (NCI) phase 3 Monoclonal antibody HER2/neu receptor
Pyrotinib, Trastuzumab, Docetaxel Pyrotinib, Trastuzumab, Docetaxel Jiangsu HengRui Medicine Co., Ltd. phase 3 Tyrosine kinase inhibitor, Monoclonal antibody, Taxane HER2/neu receptor, HER2 protein, Microtubules
Trastuzumab IV Trastuzumab IV Hoffmann-La Roche phase 3 Monoclonal antibody HER2/neu receptor
Paclitaxel + Trastuzumab Paclitaxel + Trastuzumab Institut de cancérologie Strasbourg Europe phase 3 Taxane + monoclonal antibody Microtubules + HER2/neu receptor
epirubicin - cyclophosphamide / docetaxel + trastuzumab epirubicin - cyclophosphamide / docetaxel + trastuzumab GBG Forschungs GmbH phase 3 anthracycline antibiotic/alkylating agent/taxane/monoclonal antibody topoisomerase II/DNA/HER2/neu receptor
[89Zr]Zr-crefmirlimab berdoxam 89zr-zr-crefmirlimab-berdoxam Pfizer marketed Radiolabeled Monoclonal Antibody Fibroblast Activation Protein (FAP) Not specified
Venetoclax; Rituximab venetoclax-rituximab Pfizer marketed BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab) BCL-2 (venetoclax); CD20 (rituximab) N/A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

  1. Pfizer · 7 drugs in this class
  2. argenx · 7 drugs in this class
  3. Johnson & Johnson · 2 drugs in this class
  4. German CLL Study Group · 2 drugs in this class
  5. Amgen · 2 drugs in this class
  6. Hoffmann-La Roche · 2 drugs in this class
  7. Brii Biosciences Limited · 2 drugs in this class
  8. Alexion Pharmaceuticals, Inc. · 2 drugs in this class
  9. Biotest · 2 drugs in this class
  10. Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trastuzumab/Hyaluronidase-oysk — Competitive Intelligence Brief. https://druglandscape.com/ci/trastuzumab-hyaluronidase-oysk. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: